Original research article

Evaluation of recanalisation treatment on posterior circulation ischemic stroke by Solitaire device—A multicenter retrospective study

Jianwu Long\textsuperscript{a,b}, Hao Qin\textsuperscript{c}, Hongqi Zhang\textsuperscript{a,*}

\textsuperscript{a}Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, PR China
\textsuperscript{b}Department of Neurosurgery, The 3rd Hospital of Xiamen, Fujian, PR China
\textsuperscript{c}Department of Neurosurgery, Zaozhuang Municipal Hospital, Shandong, PR China

\textbf{Abstract}

Objectives: Posterior circulation ischemic stroke (PCIS), accounting for approximately 20% of total ischemic stroke, is a sever disease that associated with high rate of morbidity and mortality. Though the effectiveness of endovascular mechanical thrombectomy has been well demonstrated in many types of ischemic stroke, it is still unclear what the outcome is in posterior circulation ischemic stroke.

Methods and materials: In current study, data was collected from 139 Chinese patients who received endovascular mechanical thrombectomy treatment with Solitaire device after acute posterior circulation ischemic stroke. We measured the mortality, symptomatic intracranial hemorrhage (SICH) and National Institutes of Health Stroke Scale (NIHSS) to evaluate the safety of endovascular mechanical thrombectomy. Meanwhile, the clinical outcome of endovascular mechanical thrombectomy was also evaluated based on recanalisation rate, NIHSS, and the modified Rankin Scale (mRS).

Results: Recanalisation was successful in 124 (89.3%) patients after surgery. Herniation was the second fatal stroke complication, out of the 6 patients suffered from herniation, 3 patients (50%) died during surgery and 2 (33%) died after surgery. As for other stroke complications such as pulmonary infection, 1 patient (4.3%) died during surgery and 1 patient (4.3%) died 3 days after surgery.

Conclusion: Our findings indicate that endovascular mechanical treatment is a safe treatment which brings clear benefit to patients suffered from posterior circulation ischemic stroke, in both the recanalisation rate and functional outcomes.

© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.

*Corresponding author at: Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, PR China.
E-mail address: hqzh@vip.163.com (H. Zhang).
http://dx.doi.org/10.1016/j.pjnns.2017.02.004
0028-3843/© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
1. Introduction

Acute basilar artery occlusion (BAO) caused the most severe types of ischemic stroke, without active treatment, the mortality rate can be up to 90% [1,2]. Anterior and posterior circulations were two important artery systems supplied by basilar artery. Based on the location where infarction occurred within the vascular territory, BAO could lead to anterior or posterior circulation ischemic stroke [1,3]. The two differs from both stroke etiology [4,5] and in terms of morbidity and mortality rate [6].

Although rarer than anterior circulation ischemic stroke (ACIS), posterior circulation ischemic stroke (PCIS) accounts for approximately 20% of all ischemic stroke [1,7–9], and without proper treatment, it might leads to potentially preventable death or severe disability [10].

Thrombolysis is an effective medical therapy for PCIS patients, however, with a strictly limited time window. Based on series of randomized large sample clinical studies, intravenous tissue-type plasminogen activator (tPA) must be applied within up 4.5 h of symptom onset [11–13].

Multiple recent studies showed consistent results that endovascular mechanical thrombectomy, a technique which clears local thrombosis by mechanical methods, can bring a clear benefit to acute anterior circulation ischemic stroke (ACIS) patients, with a prolonged treatment window [14–18]. Moreover, the combination of tPA treatment with endovascular mechanical thrombectomy had largely facilitated artery recanalisation of ischemic stroke patients [14,19,20]. Most of the studies were based on data from single center or a limited number of patients with acute ACIS [21–26]. PCIS differs from ACIS in terms of both stroke etiology [4,25] and higher rate of morbidity and mortality [6]. Evidence is needed to evaluate the clinical outcomes of endovascular mechanical thrombectomy on PCIS patients.

We undertook the current multicenter, retrospective study with large sample size on the effectiveness of endovascular mechanical thrombectomy on PCIS patients. We collected the data of 139 Chinese patients suffering from posterior circulation stroke in the database of Acute Cerebrovascular Disease (http://www.acute-cvd.com), analyzed and evaluated the clinical outcomes of these patients treated within 24 h after stroke onset. Both the safety and efficacy of endovascular mechanical thrombectomy with Solitaire device, one of the most effective recanalisation devices [27,28], on these patients, and the related clinical prognostic factors 90 days after treatment were analyzed.

2. Methods

2.1. Patient population

We collected data of 139 Chinese patients suffered acute ischemic stroke and received hospitalization in multiple centers located in China from January 2012 to December 2015. All data were acquired from the database of Acute Cerebrovascular Disease (http://www.acute-cvd.com). From the total 643 patients in the database, with either anterior (500 cases) or posterior (140 cases) circulation ischemic stroke, we selected patients based on the following criteria: (1) diagnosed as acute posterior circulation ischemic stroke, with Digital Subtraction Angiography (DSA) to confirm the location of occlusion; (2) aging from 18 to 80 years old; (3) baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 8; (4) Thrombolysis In Cerebral Infarction (TICI) is between 0 and 1, a criteria proposed by Solitaire device for patients to receive endovascular mechanical thrombectomy, assessed by Computed Tomography Angiography (CTA), Magnetic Resonance Angiography (MRA) or Digital Subtraction Angiography (DSA); (5) accumulated Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 and the pons–mesencephalon score 0–2 (see Fig. 1); (6) received endovascular treatment within 24 h after stroke onset. Although most patients suffered only basilar artery occlusion, there were some cases where vertebral artery or the posterior cerebral artery occlusion was observed.

Fig. 1 – pc-ASPECTS score: the three figures showed examples of pons–mesencephalon score from 0 to 2, as indicated in the figures.
2.2. **Endovascular thrombectomy with Solitaire**

All the patients received endovascular mechanical thrombectomy treatment under anesthesia. The surgery procedure includes following steps.

After femoral artery puncture, whole-brain vessels angiography was performed to locate the blocked artery and to confirm the perfusion state of its neighboring vessels (TICI scales). A microcatheter was penetrated through the thrombus to perform superselective angiography, in order to confirm the length of the thrombus and the perfusion state of the vessel distal to the thrombus.

To perform the endovascular mechanical thrombectomy, an 8-F guiding catheter was located at the proximal end of the thrombus through transfemoral access. Then a Rebar18 microcatheter was carefully navigated through the thrombus over a 0.014-in. microwire to reach the distal end of the thrombus (Fig. 2, up left). The end of the stent retriever was left several millimeters farther than the distal end of the thrombus. Then the microcatheter was withdrawn back to the proximal end of the thrombus and the stent retriever was allowed to fully expand all through the thrombus (Fig. 2, up right). While keeping its fully expanded status, the stent retriever was carefully pulled back to recanalise the occluded artery (Fig. 2, down left). The end of the guiding catheter was opened and the thrombus fragments along with the stent retriever were sucked out by a 50 ml syringe (Fig. 2, down right). Imaging was followed immediately to confirm the artery recanalisation.

After surgery, the patients were administered with a dual dose of 75 mg clopidogrel and 100 mg aspirin for antiplatelet treatment.

2.3. **Variables of interest**

2.3.1. **Safety evaluation**

The safety of endovascular mechanical thrombectomy was evaluated by the following variables: (1) mortality rate 90 days after surgery; (2) the rate of symptomatic intracranial hemorrhage (SICH). The judgment of SICH was based on the evidence of CT or MRI. SICH was defined as the intracranial hemorrhage within 22–36 h after treatment as confirmed by imaging techniques, accompanied with NIHSS decrease ≥ 4.

2.3.2. **Effectiveness evaluation**

The effectiveness of endovascular mechanical thrombectomy was evaluated as the recanalisation rate, represented by TICI (2 or 3). Besides, the NIHSS score at discharge and 90 days after endovascular mechanical thrombectomy surgery were analyzed. Modified Rankin Scale (mRS) 90 days post surgery was measured. The complications such as symptomatic intracerebral hemorrhage, vessel dissection and the occlusion of unaffected vessels were monitored as well.

2.3.3. **Factors affecting clinical outcomes**

We monitored the factors that could potentially affect clinical outcomes, including (1) factors related with patients: (i) age, (ii) baseline blood pressure, (iii) diabetes, (iv) NIHSS or GCS before treatment; (2) factors related with endovascular mechanical thrombectomy: (i) anesthesia, (ii) number of endovascular mechanical thrombectomy received, (iii) length of time from arriving hospital to recanalisation, (iv) type of stroke (TOAST classification), (v) combined treatment regime, (vi) symptomatic hemorrhage.

2.4. **Statistical analysis**

Descriptive analysis on frequencies or percentages of classified variables was performed. Chi-square test was performed on continuous variables that fit normal distribution. For the continuous variables that did not fit normal distribution, median and quartile values were used for analysis. To compare patients with favorable vs. unfavorable prognosis, t-test or rank sum test was performed on the continuous variables, while chi-square test or Fisher exact probability test was performed on classified variables. One-way analysis of variance (ANOVA) was performed on factors predicting the change of clinical phase. All the analysis was performed on software SPSS 19.0.

3. **Results**

3.1. **Patient data**

In this study, we collected data of 139 Chinese patients suffered acute ischemic stroke and received endovascular mechanical recanalisation from the database of Acute Cerebrovascular Disease (http://www.acute-cvd.com). In our collection, there were 105 male and 34 female patients, with an average age of 59.7 ± 13.6. The median pre thrombectomy NIHSS score was 23 (IQR: 16–28) and the median pre-thrombectomy GCS was 9 (IQR: 7–10) (Table 1).

3.2. **Treatment results and clinical outcomes**

In current dataset, the median onset-to-door time was 310 (IQR: 240–498) min and the median surgery time was 72 (IQR:
50–120) min. 14 patients died during the surgery (mortality rate: 10%) and the mortality rate reached 14.3% (20/139) by the time of 90 days after surgery. Favorable outcomes (mRS scores: 0–2) were achieved in 34 patients at discharge (24.5% of all the patients, 27.2% of the survivors). By the time of 90 days after surgery, favorable outcomes (mRS scores: 0–2) were achieved in 58 patients (41.7% of all the patients, 48.7% of the survivors).

The patients’ median post-thrombectomy NIHSS score was 17.0 (IQR: 7.5–24.5) at discharge after endovascular mechanical thrombectomy surgery. Recanalisation was successful in 124 patients (89.2%) with TICI grades ≥ 2b; furthermore, 62.1% of these patients achieved TICI grade 3. By the time of 90 days after surgery, the median NIHSS score was 10.0 (IQR: 4.8–20.0) (Table 2). Endovascular mechanical thrombectomy surgery with Solitaire device had improved NIHSS score significantly, both at discharge (P < 0.0001) and 90 days after surgery (P < 0.0001).

However, seven kinds of stroke complications were observed in the patients during or after surgery: 23 patients (16.5%) suffered from pulmonary infection, 5 patients (3.6%) suffered from hemorrhagic transformation, 6 patients (4.3%) suffered from herniation, 1 patient (0.7%) suffered from hydrocephalus, 1 patient (0.7%) suffered from gastrointestinal hemorrhage, 4 patients suffered from cardiac or respiratory arrest (2.9%) and 1 patient (0.7%) suffered from recurrent stroke (Table 2).

### Table 1 - Patient characteristics.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>139</td>
</tr>
<tr>
<td>Male (%)</td>
<td>105 (75.5)</td>
</tr>
<tr>
<td>Age (year), mean (SD)</td>
<td>59.7 (13.6)</td>
</tr>
<tr>
<td>Pre-thrombectomy NIHSS, median (IQR)</td>
<td>23 (16–28)</td>
</tr>
<tr>
<td>Pre-thrombectomy GCS, median (IQR)</td>
<td>9 (7–10)</td>
</tr>
</tbody>
</table>

### Table 2 - Treatment outcomes.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset-to-door time (min), median (IQR)</td>
<td>310 (240–498)</td>
</tr>
<tr>
<td>Surgery time (min), median (IQR)</td>
<td>72 (50–120)</td>
</tr>
<tr>
<td>TICI after surgery, n (% of all, % of survivors)</td>
<td>24 (89.2, 99.2)</td>
</tr>
<tr>
<td>≥2b</td>
<td>34 (24.5, 27.2)</td>
</tr>
<tr>
<td>NIHSS at discharge, median (IQR)</td>
<td>17.0 (7.5–24.5)</td>
</tr>
<tr>
<td>mRS at discharge, n (% of all, % of survivors)</td>
<td>10.0 (4.8–20.0)</td>
</tr>
<tr>
<td>Mortality at discharge, n (%)</td>
<td>14 (10)</td>
</tr>
<tr>
<td>NIHSS 90 days after surgery, median (IQR)</td>
<td>10.0 (4.8–20.0)</td>
</tr>
<tr>
<td>mRS 90 days after surgery, n (% of all, % of survivors)</td>
<td>58 (41.7, 48.7)</td>
</tr>
<tr>
<td>Mortality 90 days after surgery, n (%)</td>
<td>20 (14.4)</td>
</tr>
<tr>
<td>Stroke complications, n (%)</td>
<td></td>
</tr>
<tr>
<td>Pulmonary infection</td>
<td>23 (16.5)</td>
</tr>
<tr>
<td>Hemorrhagic transformation</td>
<td>5 (3.6)</td>
</tr>
<tr>
<td>Herniation</td>
<td>6 (4.3)</td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Gastrointestinal hemorrhage</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Cardiac or respiratory arrest</td>
<td>4 (2.9)</td>
</tr>
<tr>
<td>Recurrent stroke</td>
<td>1 (0.7)</td>
</tr>
</tbody>
</table>

### 4. Discussion

Endovascular mechanical thrombectomy with a stent retriever was now the most recommended treatment in patients suffered from BAO of anterior cerebral circulation [14–18]. However, on the other hand, there were only a few small sample studies focusing on the safety and effectiveness of endovascular mechanical thrombectomy treatment on patients suffered from acute posterior circulation ischemic stroke, another important stroke type caused by BAO [22,29–32]. To the best of our knowledge, this study was the first multi-center study with large sample size to evaluate the safety and effectiveness of endovascular mechanical thrombectomy treatment with Solitaire device on acute posterior circulation ischemic stroke on 139 Chinese patients.

Our study showed improved outcomes of endovascular mechanical thrombectomy treatment with Solitaire device on patients suffered from acute posterior circulation ischemic stroke than reported results with either traditional treatment [2] or thrombolysis therapy [33,34] in the following aspects: reduced mortality rate, higher recanalisation rate and better clinical outcomes. As compared with traditional treatment, our mechanical thrombectomy treatment with Solitaire device showed a much lower mortality rate (10% after surgery and 14.3% by 90 days vs. traditional 40%) as well as improved outcomes (34% at mRS 0–2 vs. traditional 17% at mRS 0–3) [2]. By 90 days after treatment, our method showed an even better outcome (58% at mRS 0–2) than that with traditional treatment. As compared with another widely used treatment for ischemic stroke, thrombolysis therapy, our method achieved a higher recanalisation rate (89.2% vs. 53–65%) [33,34]. All these results suggest that mechanical thrombectomy with Solitaire device could serve as a safe and efficient treatment for patients suffered from acute posterior circulation ischemic stroke, which could provide better outcomes than traditional treatment or thrombolysis therapy. Furthermore, even when compared with mechanical thrombectomy treatment with other devices, such as Merci device, our mortality rate with Solitaire device was much lower (10% after surgery and 14.3% by 90 days vs. 43–50% with Merci) along with a much shorter operation time (73 with Solitaire vs. 129 min with Merci) [40]. Our operation time was comparable to a recent single center study with Solitaire device (73 vs. 61 min), but with a lower mortality rate (14.3 vs. 32%) [22]. These results suggest that both our treatment strategy and operation techniques are competent to the best level of mechanical thrombectomy.

In current study, stroke complications during and after surgery have a strong correlation with after surgery mortality (65% of the 20 deaths). Cardiac or respiratory arrest was the most fatal stroke complication and all four patients suffered from it died during surgery (100%). Herniation was the second fatal stroke complication, out of the six patients suffered from herniation, three (50%) died during surgery and two (33%) died after surgery. As for other stroke complications such as pulmonary infection, one patient (4.3%) died during surgery and one patient (4.3%) died three days after surgery. Two patients suffered from hemorrhagic transformation (40%) died during surgery. Developing strategies to monitor and reduce...
stroke complications is a potential target to further improve the safety and efficacy of mechanical thrombectomy treatment on acute posterior circulation ischemic stroke patients.

Conflict of interest

None declared.

Acknowledgment and financial support

This study was supported by National Tech & Sci Supporting Plan Fund (No. 2011BAI08B00).

Ethics

The work described in this article has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to Biomedical journals.

REFERENCES


